Multi-Marker Risk Scoring Optimizes the Identification of Clinically Significant Prostate Malignancies

Article Impact Level: HIGH
Data Quality: STRONG
Summary of  Annals of Internal Medicine, ANNALS-25-04753. https://doi.org/10.7326/ANNALS-25-04753
Dr. Thorgerdur Palsdottir et al.

Points

Karolinska Institutet researchers conducted a large population-based study involving 12,670 men aged 50 to 74 to evaluate an advanced prostate cancer screening method.
The multi-marker Stockholm3 blood test successfully identified 90% of aggressive prostate cancer cases compared to a significantly lower detection rate of 74% for traditional PSA tests.
Investigators tracked all screening participants for two years using Swedish national registries to actively identify clinically significant tumors missed during the baseline clinical evaluations.
The diagnostic model combined plasma protein biomarkers, polygenic risk scores, and clinical variables to successfully reduce the number of serious missed interval cancer diagnoses.
Diagnostic sensitivity was significantly maximized without expanding the proportion of low-risk men who were incorrectly classified as high risk or subjected to unnecessary healthcare procedures.

Summary

Initiated to optimize early diagnostic pathways and reduce overdiagnosis, this study evaluated the clinical performance of the blood-based Stockholm3 multivariable risk score compared to standard prostate-specific antigen (PSA) testing. Standard PSA screening remains highly controversial due to its poor specificity, which frequently fails to detect aggressive malignancies while simultaneously exposing a high proportion of men to unnecessary secondary investigations and invasive tissue biopsies. The research sought to determine if a comprehensive screening algorithm—integrating baseline PSA, plasma protein biomarkers, polygenic risk scores, and distinct clinical variables—could accurately isolate high-risk malignancies without expanding unnecessary medical follow-ups.

Using a large population-based cohort from the STHLM3-MRI study in Sweden, investigators enrolled and monitored 12,670 men between the ages of 50 and 74. All study participants received paired baseline evaluations with both standard PSA and the Stockholm3 multivariable testing panel and were subsequently tracked for two years via national cancer registries to capture missed interval cases. Longitudinal follow-up data documented that a total of 443 men within the population cohort were diagnosed with clinically significant, aggressive prostate cancer. Statistical analysis demonstrated that the Stockholm3 algorithm identified 90% of these high-risk aggressive cases, whereas traditional single-agent PSA testing identified only 74% of the identical malignant cohort.

Diagnostic superiority was achieved without an associated rise in the false-positive rate, as the proportion of men incorrectly classified as high risk remained highly similar between the two testing protocols. The Stockholm3 multivariable test missed significantly fewer serious malignancies, demonstrating enhanced diagnostic sensitivity for truly lethal phenotypes while maintaining stable clinical specificity margins. While extended longitudinal monitoring is still required to determine explicit hazard ratios for prostate cancer-specific mortality and evaluate long-term oncological survival benefits, these initial data suggest that shifting toward multi-marker risk scoring represents a highly viable screening strategy to refine patient selection for secondary magnetic resonance imaging and target biopsies.

Link to the article: https://www.acpjournals.org/doi/10.7326/ANNALS-25-04753

References

Palsdottir, T., Micoli, C., Eklund, M., Grönberg, H., Jäderling, F., Tilki, D., Lin, D. W., Cooperberg, M. R., Eggener, S. E., Oeffinger, K. C., Nordström, T., & Vigneswaran, H. T. (2026). Stockholm3–magnetic resonance imaging population-based prostate cancer screening study: Two-year follow-up. Annals of Internal Medicine, ANNALS-25-04753. https://doi.org/10.7326/ANNALS-25-04753